reports
- Maria Vara
- Oscar Haffen Lamm
Coverage update
Given team and strategy changes, Oscar Haffen Lamm is now assuming coverage of Medincell, Camurus, Valneva, Aelis Pharma, Abivax, Calliditas, Egetis Therapeutics, Basilea, Geneuro, Achilles, Valerio, Innate Pharma, Morphosys, Inventiva Pharma, Vicore, DBV Technologies, and Genfit.Maria Vara is now
BSLN BASILEA PHARMACEUTICA AG
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ALMDT MEDIAN TECHNOLOGIES
EGTX EGETIS THERAPEUTICS AB
7CA CAMURUS AB
VICO VICORE PHARMA HOLDING AB
5142 ACHILLES CORP.
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
XVIVO XVIVO PERFUSION AB
GNRO GENEURO SA
BONEX BONESUPPORT HOLDING AB
MOR MORPHOSYS AG
MED MEDARTIS AG
MEDCL MEDINCELL SA
CALTX CALLIDITAS THERAPEUTICS AB
IVA INVENTIVA ADS
CLNK B CELLINK AB
GNFT GENFIT
AELIS AELIS FARMA SA
ONWD ONWARD OPPORTUNITIES LIMITED
ALONX ONXEO
ABVX ABIVAX
- Alex Cogut
Coverage update
Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte
CLLS CELLECTIS ADS
ADAP ADAPTIMMUNE THERAPEUTICS ADS
TNG TRANSGENE SA
IPH INNATE PHARMA SA CLASS A
CYAD CELYAD ONCOLOGY
HNSA HANSA BIOPHARMA AB
SIGHT GENSIGHT BIOLOGICS SA
5142 ACHILLES CORP.
POXEL POXEL SA
BCART BIOCARTIS GROUP NV
CRSP CRISPR THERAPEUTICS AG
GNMSY GENMAB A/S
BNTX BIONTECH SE
CALTX CALLIDITAS THERAPEUTICS AB
IMCR IMMUNOCORE HOLDINGS ADS
IMTX IMMATICS
GLG GALAPAGOS
- Healthcare Team
- Alex Cogut
- Ingird Gafanhão
- Maria Vara
- Olga Smolentseva
- Oscar Haffen Lamm
- Valliant Campagne
Precision TIL Therapy
Achilles Therapeutics is a UK-based, clinical-stage biotech focusing on the development of T cell therapies targeting clonal neoantigens. In a nutshell, there are two differentiation aspects to Achilles' approach: i) targeting clonal neoantigens, which are thought to be expressed on the surface of
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.